In a report published Wednesday, Credit Suisse reiterated its Neutral rating on Gilead Sciences GILD, and raised its price target from $54.00 to $65.00.
Credit Suisse noted, “Slight Q3 beat driven primarily by higher product sales. GILD reported after the market close yesterday, posting an EPS of $1.00 (vs. $0.96/$0.93 for Credit Suisse/consensus). The beat was driven by higher product sales ($2.43B vs. $2.37B/$2.33B for Credit Suisse/consensus). Truvada delivered a strong Q3, posting sales of $800M (vs. $774M/$762M for Credit Suisse/consensus). GILD also raised guidance on 2012 net product sales from $8.8B-$9.0B to $9.1B-$9.2B. We made housekeeping changes to our model; there were no major changes. We are raising our 2012/2013/2014 EPS estimates to $.85/$4.64/$6.02 (from $3.83/$4.57/$5.94) respectively.”
Gilead Sciences closed on Tuesday at $64.91.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in